The Burden of Migraine in Brazil's Private Healthcare System: Results From the Brazil Migraine Real-World Evidence (BREM) Study
Author(s)
Camila Penteado, MD1, arcangela valle, MBA1, Alexandre Vieira Ribeiro da Silva, MD2, Nathália K. Assumpção, MBA2, Andrés F. Rivera, N/A3, Aviva Peyser Levin, MBA4, Rinat Ribalov, BSc, MHA5, Gabriela Kivelevitch, MD4;
1Teva Pharmaceutical Industries Ltd., São Paulo, Brazil, 2Sandbox – Data for Health, São Paulo, Brazil, 3Funcional Health Tech, São Paulo, Brazil, 4Teva Pharmaceutical Industries Ltd., International Markets Medical Affairs, Tel Aviv, Israel, 5Teva Pharmaceutical Industries Ltd., Global Health Economics Outcomes and Values, Tel Aviv, Israel
1Teva Pharmaceutical Industries Ltd., São Paulo, Brazil, 2Sandbox – Data for Health, São Paulo, Brazil, 3Funcional Health Tech, São Paulo, Brazil, 4Teva Pharmaceutical Industries Ltd., International Markets Medical Affairs, Tel Aviv, Israel, 5Teva Pharmaceutical Industries Ltd., Global Health Economics Outcomes and Values, Tel Aviv, Israel
Presentation Documents
OBJECTIVES: The Brazil Migraine Real-World Evidence study aimed to describe the burden of migraine in adults (≥18 years) within Brazil's private healthcare system, in terms of healthcare resource utilization (HCRU) and direct costs.
METHODS: This retrospective, observational study analyzed private health insurance claim data from 7,382,457 patients between January 2019 and June 2024, identifying 22,417 adults diagnosed with migraine (ICD-10 G43.X). Patients with migraine were compared with controls without migraine (matched for age, gender, geographical state, comorbidities, and health insurance modality). Kruskal-Wallis and Chi-square tests were used for comparisons between the groups.
RESULTS: Patients with migraine (female: 73.6%; average age: female, 47 years; male, 44 years) had comorbidities, including musculoskeletal disease (female: 24.8%; male: 7.5%), cardiovascular disease (female: 12.6%; male: 4.9%), and depression (female: 12.1%; male: 2.6%). Compared with controls, patients with migraine attended significantly more consultations (12.73 vs 8.42, p=0.0204) and exams (30.61 vs 25.54, p<0.001) per person. Mean emergency room visits were more frequent in patients with migraine versus controls (per person: 3.98 vs 2.20, p<0.001), as were emergency hospitalizations (per person: 0.14 vs 0.10, p<0.001). Patients with migraine were approximately 1.6 times more likely to receive individual psychotherapy and physical therapy sessions (rehabilitation - musculoskeletal pathology; 4.84% and 14.04%, respectively) versus controls (3.07% and 9.23%, respectively, both p<0.001). Patients with migraine were significantly more likely to undergo laboratory tests, neuroimaging, and specific electrophysiological exams compared with controls (p<0.0001). Significantly higher median costs per exam (R$ 8.40 vs 7.50), emergency room visit (R$ 127.97 vs 103.25), and emergency hospitalization (R$ 5750.00 vs 5482.68) were observed for patients with migraine versus controls (all p<0.001).
CONCLUSIONS: These findings demonstrate the burden of migraine on Brazil’s healthcare system through increased HCRU and direct costs. Implementation of targeted treatments, such as calcitonin gene-related pathway monoclonal antibodies, and improved diagnostic and management protocols may alleviate this burden.
METHODS: This retrospective, observational study analyzed private health insurance claim data from 7,382,457 patients between January 2019 and June 2024, identifying 22,417 adults diagnosed with migraine (ICD-10 G43.X). Patients with migraine were compared with controls without migraine (matched for age, gender, geographical state, comorbidities, and health insurance modality). Kruskal-Wallis and Chi-square tests were used for comparisons between the groups.
RESULTS: Patients with migraine (female: 73.6%; average age: female, 47 years; male, 44 years) had comorbidities, including musculoskeletal disease (female: 24.8%; male: 7.5%), cardiovascular disease (female: 12.6%; male: 4.9%), and depression (female: 12.1%; male: 2.6%). Compared with controls, patients with migraine attended significantly more consultations (12.73 vs 8.42, p=0.0204) and exams (30.61 vs 25.54, p<0.001) per person. Mean emergency room visits were more frequent in patients with migraine versus controls (per person: 3.98 vs 2.20, p<0.001), as were emergency hospitalizations (per person: 0.14 vs 0.10, p<0.001). Patients with migraine were approximately 1.6 times more likely to receive individual psychotherapy and physical therapy sessions (rehabilitation - musculoskeletal pathology; 4.84% and 14.04%, respectively) versus controls (3.07% and 9.23%, respectively, both p<0.001). Patients with migraine were significantly more likely to undergo laboratory tests, neuroimaging, and specific electrophysiological exams compared with controls (p<0.0001). Significantly higher median costs per exam (R$ 8.40 vs 7.50), emergency room visit (R$ 127.97 vs 103.25), and emergency hospitalization (R$ 5750.00 vs 5482.68) were observed for patients with migraine versus controls (all p<0.001).
CONCLUSIONS: These findings demonstrate the burden of migraine on Brazil’s healthcare system through increased HCRU and direct costs. Implementation of targeted treatments, such as calcitonin gene-related pathway monoclonal antibodies, and improved diagnostic and management protocols may alleviate this burden.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
EE15
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Neurological Disorders